Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863479 | 1.00 | RAB9A (0.45) | RAB9ATNFNOD1PIK3CDFADS1 | |
| SCHEMBL864937 | 0.81 | PIK3CD (0.50) | TNFPIK3CDEGFRAURKARPS6KB1 | |
| SCHEMBL863938 | 0.81 | PIK3CD (0.49) | PIK3CDEGFRKDM4EAURKARPS6KB1 | |
| SCHEMBL864936 | 0.81 | PIK3CD (0.50) | TNFPIK3CDEGFRAURKARPS6KB1 | |
| SCHEMBL863937 | 0.81 | PIK3CD (0.49) | PIK3CDEGFRKDM4EAURKARPS6KB1 | |
| SCHEMBL864075 | 0.79 | PIK3CD (0.41) | TNFPIK3CDEGFRKDM4EAURKA | |
| SCHEMBL864074 | 0.79 | PIK3CD (0.41) | TNFPIK3CDEGFRKDM4EAURKA | |
| Formic Acid SCHEMBL865074 | 0.79 | TNF (0.39) | RAB9ATNFNOD1PIK3CDFADS1 | |
| Formic Acid SCHEMBL865075 | 0.79 | TNF (0.39) | RAB9ATNFNOD1PIK3CDFADS1 | |
| SCHEMBL864030 | 0.79 | PIK3CD (0.46) | TNFPIK3CDEGFRKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | RAB9A 1316/4885TNF 1114/4885NOD1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.